Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01908426
Title Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Recruitment Completed
Gender
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

hepatocellular carcinoma

Therapies

Cabozantinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.